Asuragen Licenses BRAF V600E Mutation for Cancer Testing | GenomeWeb

Asuragen said this week that it has taken a non-exclusive license to the BRAF V600E mutation from Johns Hopkins University for use in its CLIA laboratory for clinical research and patient testing for a range of cancers.

The presence of the V600E mutation in the BRAF oncogene has been shown to impact prognosis and the prediction of therapeutic response in colorectal cancer and also predicts a poorer prognosis in thyroid cancer, Asuragen said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.